We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Nevro (NVRO) Up 9.6% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Nevro (NVRO - Free Report) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Nevro due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Nevro Q3 Loss Narrower Than Expected, 2019 Guidance Raised
Nevro reported third-quarter 2019 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 85 cents. The company had incurred a loss of 37 cents in the year-ago quarter.
The company posted revenues of $100.2 million, which surpassed the Zacks Consensus Estimate by 6.2%. The figure also rose 4.7% year over year.
Quarter Highlights
In the quarter under review, international revenues were $16 million, flat year over year but up 5% at constant currency.
U.S. revenues for the quarter totaled $100.2 million, up 5% year over year. The upside was primarily driven by SCS procedure growth.
Additionally, U.S. patient trials and permanent implants each grew 18% on a year-over-year basis. The company also launched the Senza Omnia SCS System commercially in the United States.
Margins
Gross profit totaled $69.9 million, up 4% year over year. Gross margin was 69.8%, down 50 basis points.
Operating expenses rose 12.3% year over year to $85.9 million. Research and development expenses totaled $13 million, up 4.3% year over year.
Sales, general and administrative expenses were up 13.9% year over year to $72.9 million.
Guidance
Nevro raised its revenue guidance for 2019.
The company now expects revenues in the range of $368-$374 million compared with the previous expectation of $383-$386 million.
Gross margin is expected in the range of 68-70% as a percentage of revenues.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 9.56% due to these changes.
VGM Scores
At this time, Nevro has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Nevro has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Nevro (NVRO) Up 9.6% Since Last Earnings Report?
It has been about a month since the last earnings report for Nevro (NVRO - Free Report) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Nevro due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Nevro Q3 Loss Narrower Than Expected, 2019 Guidance Raised
Nevro reported third-quarter 2019 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 85 cents. The company had incurred a loss of 37 cents in the year-ago quarter.
The company posted revenues of $100.2 million, which surpassed the Zacks Consensus Estimate by 6.2%. The figure also rose 4.7% year over year.
Quarter Highlights
In the quarter under review, international revenues were $16 million, flat year over year but up 5% at constant currency.
U.S. revenues for the quarter totaled $100.2 million, up 5% year over year. The upside was primarily driven by SCS procedure growth.
Additionally, U.S. patient trials and permanent implants each grew 18% on a year-over-year basis. The company also launched the Senza Omnia SCS System commercially in the United States.
Margins
Gross profit totaled $69.9 million, up 4% year over year. Gross margin was 69.8%, down 50 basis points.
Operating expenses rose 12.3% year over year to $85.9 million. Research and development expenses totaled $13 million, up 4.3% year over year.
Sales, general and administrative expenses were up 13.9% year over year to $72.9 million.
Guidance
Nevro raised its revenue guidance for 2019.
The company now expects revenues in the range of $368-$374 million compared with the previous expectation of $383-$386 million.
Gross margin is expected in the range of 68-70% as a percentage of revenues.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 9.56% due to these changes.
VGM Scores
At this time, Nevro has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Nevro has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.